## SEC Form 4

П

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject t	h
Section 16. Form 4 or Form 5	.0
obligations may continue. See	
Instruction 1(b).	

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burder hours per response: 0.5

1. Name and Address of Reporting Person* DP VII ASSOCIATES LP			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Evoke Pharma Inc</u> [EVOK]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
DP VILAS	SOCIATES I	<u>_P</u>		Director	X 10% Owner				
(Last) C/O DOMAIN	(First) ASSOCIATES	(Middle) 5, LLC	3. Date of Earliest Transaction (Month/Day/Year) 09/30/2013	Officer (give title below)	Other (specify below)				
ONE PALME	R SQUARE		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filir	ng (Check Applicable				
(Street) PRINCETON	NJ	08542		Line) X Form filed by One Rep Form filed by More that Person	6				
(City)	(State)	(Zip)							

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities A Disposed Of ( 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)
Common Stock	09/30/2013		С		19,006	Α	(1)	19,006	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	of (İ	(D) (Instr. and 5)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Series A Preferred Stock	(1)	09/30/2013		С			19,006	(1)	(1)	Common Stock	19,006	\$0	0	D	

#### Explanation of Responses:

1. All outstanding shares of Series A Preferred Stock were automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date.

#### Remarks:

/s/Kathleen K. Schoemaker, <u>Managing Member of One</u> <u>Palmer Square Associates VII</u>, <u>09/30/2013</u> <u>LLC, General Partner of DP</u> <u>VII Associates, L.P.</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.